ClinicalTrials.gg
RecruitingNCT05546060Updated Sep 19, 2022

Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

A Phase 1 interventional study of Venetoclax and Dexamethasone in Hemophagocytic Lymphohistiocytosis, sponsored by Beijing Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-19.

Sponsored by Beijing Friendship Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital — 7 open to participants now, 7 under way, 3 of them phase 3. Lymphohistiocytosis, Hemophagocytic · Beijing Friendship Hospital.

Planned enrollment
12th of 17
20 · median 30
Started
2022
with 4 others
Phase 1
Only one
of the 21
Registered
12th of 21
by date

Among the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2022, is the only one in phase 1, and was the 12th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

7 of the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, or all of them as a file.
02

Study summary

This study aimed to investigate the efficacy and safety of venetoclax combined with dexamethasone and etoposide as a salvage therapy for hemophagocytic lymphohistiocytosis.

Read the detailed description

Hemophagocytic lymphohistiocytosis (HLH) is a rare and aggressive disease with high mortality and poor prognosis. The HLH-94 and HLH-04 regimens are most commonly used, but approximately 30% of the patients remain unresponsive. Currently, there is no unified evidence-based salvage treatment. There is no unified salvage regimen. This study plans to enroll 20 patients with refractory and recurrent hemophagocytic lymphohistiocytosis. Subjects will receive venetoclax combined with dexamethasone and etoposide for 8 weeks.The safety was evaluated once a week, and the efficacy was evaluated once every 2 weeks. Overall response rate will be evaluated at 8 weeks. Patients were followed up every 3 months thereafter.

03

Conditions studied

  • Hemophagocytic Lymphohistiocytosis

Keywords

  • Hemophagocytic Lymphohistiocytosis
  • Venetoclax
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥18 years old, expected survival time more than 3 months;
  • met HLH-2004 diagnostic criteria;
  • score 0-2;
  • interval: male ≤450ms, female ≤470ms;
  • and ALT ≤3.0 , TB ≤1.5×ULN;serum creatinine≤1.5×ULN,or CrCL ≥ 50mL/min;、APTT、PT ≤1.5×ULN;
  • without pregnancy or lactation, and agree to during and for at least 6 months after the study;
  • signed .

Exclusion criteria

Exclusion Criteria:

  • patients with unrelated to HLH, except for fully recovered non-melanoma skin cancer and carcinoma in situ;
  • patients participated in other clinical trials within 4 weeks;
  • previously treated with Bcl-2 inhibitors;
  • unable to take oral medication;
  • history of substance abuse or patients with mental illness;
  • severe infection;
  • cardiovascular disease, II-IV;
  • allergic to venetoclax or etoposide.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Venetoclax Combined With Dexamethasone and Etoposide

    Patients who met the inclusion criteria will receive venetoclax combined with dexamethasone and etoposide for 8 weeks.

    Drug: Venetoclax · Drug: Dexamethasone · Drug: Etoposide

Interventions

  • Venetoclax 100mg qd d1,200mg qd d2,400mg qd d3-56

  • Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56

  • Etoposide 75mg/m2 qw d1-56

06

What researchers measure

Primary outcomes

  1. Overall response rate

    The percentage of cases with complete response (CR) and partial response (PR) after treatment in the total evaluable cases

    Time frame: 1 year

  2. Incidence and severity of adverse effects

    The percentage of cases with adverse effects and its severity.

    Time frame: 1 years

Secondary outcomes

  1. Overall survival

    OS is defined as the time from the initiaion of treatment to death from any cause or July 2025.

    Time frame: 1 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Jul 2025, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Sep 19, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Jul 1, 2025
CompletionEst.
Oct 1, 2025
Last update
Sep 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05546060
Responsible party
Zhao Wang (Professor and Head of hematology, Beijing Friendship Hospital) — Principal investigator
First posted
Sep 19, 2022
Start date
Jul 1, 2022
Primary completion
Jul 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Sep 19, 2022

Study contacts

Zhao Wang, MD
Contact
wangzhao@ccmu.edu.cn
63138303
Zhao Wang, MD
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Dexamethasone · Etoposide

Start the discussion